JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.